论文部分内容阅读
目的 改进基因修饰的肿瘤细胞疫苗的效力。方法 在小鼠乳腺癌细胞系EMF6 和一个已被含有IL - 2和TNFα融合基因的逆转录病毒载体XdF转染的EMF6 亚系 (T2 -EMF6)中表达B7 1基因。结果 免疫 /侵袭实验表明 ,与单基因转导的肿瘤细胞相比 ,IL - 2-TNFα/B7 1共同修饰的肿瘤细胞具有较低的致瘤性和较优的疫苗效力 (P <0 0 5)。在各种肿瘤细胞的免疫接种后三周 ,进行混合淋巴细胞培养实验和51 Cr释放实验来检测动物的细胞免疫活性 ,IL - 2 -TNFα和B7 1共同作用诱导了比其中的任意一个单独作用更强的抗肿瘤应答 (比IL - 2 -TNFα高 2 5% ,比B7 1高 2 0 % )。结论 IL - 2 -TNFα和B7 1协同作用可提高他们所修饰的肿瘤细胞的疫苗效力。
Objective To improve the efficacy of genetically modified tumor cell vaccines. Methods The B7 1 gene was expressed in mouse breast cancer cell line EMF6 and in an EMF6 subline (T2 -EMF6) that has been transfected with the retroviral vector XdF containing the fusion gene IL-2 and TNFα. Results Immuno / invasion assay showed that tumor cells co-modified with IL-2-TNFα / B7 1 had lower tumorigenicity and better vaccine efficacy than single-gene transduced tumor cells (P <0.05 ). Three weeks after the immunization of various tumor cells, mixed lymphocyte culture experiments and 51 Cr release assays were performed to examine the cellular immune activity of the animals, and the combined action of IL-2-TNFa and B7 1 induced either of these effects alone Stronger anti-tumor response (25% higher than IL-2-TNFa and 20% higher than B7 1). Conclusion The synergistic effect of IL - 2 - TNFa and B7 1 can enhance the vaccine efficacy of the modified tumor cells.